Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Apoptotic Cells in Rheumatoid Arthritis
NCT02903212Phase 2Unknown
- Sponsor
- CHU de Besançon
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of autologous apoptotic cells in rheumatoid arthritis (RA), sponsored by CHU de Besançon. Primary endpoint: Tolerance of apoptotic cells injection at 12 weeks. Status: unknown.
02
Drugs
autologous apoptotic cells
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02903212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903212.